Preoperative prediction of growth hormone (GH)/insulin-like growth factor-1 (IGF-1) axis modification and postoperative changes in candidates for bariatric surgery

Obesity Surgery

Volumn 23, Issue 5, 2013, Pages 594-601

  Mittempergher, Francesco ^a   Pata, Giacomo ^b   Crea, Nicola ^a   Di Betta, Ernesto ^a   Vilardi, Antonio ^a   Chiesa, Deborah ^a   Nascimbeni, Riccardo ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b Brescia Civic Hospital   (Italy)

Author keywords

Bariatric surgery; Growth hormone; Insulin like growth factor 1; Lipid metabolism; Obesity

Indexed keywords

CHOLESTEROL; FIBRINOGEN; GROWTH HORMONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TRIACYLGLYCEROL;

ADULT; ARTICLE; BILIOPANCREATIC BYPASS; CLINICAL TRIAL; FEMALE; GASTRIC BANDING; GROWTH HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; OBSERVATIONAL STUDY; POSTOPERATIVE PERIOD; PREDICTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; WAIST CIRCUMFERENCE; WAIST HIP RATIO;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; BODY MASS INDEX; CHOLESTEROL; FEMALE; FOLLOW-UP STUDIES; GASTROPLASTY; HOMEODOMAIN PROTEINS; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; ITALY; MALE; MIDDLE AGED; OBESITY, MORBID; PATIENT SELECTION; POSTOPERATIVE PERIOD; PREDICTIVE VALUE OF TESTS; PREOPERATIVE PERIOD; PROSPECTIVE STUDIES; TRANSCRIPTION FACTORS; TRIGLYCERIDES; WEIGHT LOSS;

EID: 84876491565     PISSN: 09608923     EISSN: 17080428     Source Type: Journal    
DOI: 10.1007/s11695-012-0820-z     Document Type: Article

References (31)

1. Maccario M, Valetto MR, Savi P, et al. Maximal secretory capacity of samatotrope cells in obesity: comparison with GH deficiency. Int J Obes Relat Metab Disord. 1997;21:27-32.
2. Scacchi M, Pincelli AI, Cavagnini F. Growth hormone in obesity. Int J Obes Relat Metab Disord. 1999;23:262-71.
3. Pardina E, Ferrer R, Lecube A, et al. The relationship between IGF-1 and CRP, NO, leptin and adiponectin during weight loss in the morbidly obese. Obes Surg. 2010;20:623-33.
4. Kreitschmann-Andermahr I, Suarez P, Jennings R, et al. GH/IGF-1 regulation in obesity-mechanisms and practical consequences in children and adults. Horm RES Paediatr. 2010;73:153-60.
5. Garten A, Schuster S, Kiess W. The insulin-like growth factors in adipogenesis and obesity. Endocrinol Metab Clin North Am. 2012;41:283-95. v-vi.
6. Misra M, Bredella MA, et al. Lower growth hormone and higher cortisol are associated with greater visceral adiposity, intramyocellular lipids, and insulin resistance in overweight girls. Am J Physiol Endocrinol Metab. 2008;295:E385-92.
7. Attallah H, Friedlander AL, Hoffman AR, et al. Visceral obesity, impaired glucose tolerance, metabolic syndrome, and growth hormone therapy. Growth Horm IGF Res. 2006;16(Suppl A):62-7.
8. Gastrointestinal surgery for morbid obesity: National Institute of Health Consensus Development Conference Statement. Am J Clin Nutr. 1992; 55(suppl 2):S615-S19.
9. Mittempergher F, Di Betta E, Crea N, et al. Our experience in selecting patients for bariatric surgery. Ann Ital Chir. 2007;78:487-92.
10. Frystyk J. Free insulin-like growth factors - measurements and relationships to growth hormone secretion and glucose homeostasis. Growth Horm and IGF Res. 2004;14:337-75.
11. Luque RM, Kineman RD. Impact of obesity on the growth hormone axis: evidence for a direct inhibitory effect of hyperinsulinemia on pituitary function. Endocrinology. 2006;147:2754-63.
12. Crea N, Pata G, Di Betta E, et al. Long-term results of biliopancreatic diversion with or without gastric preservation for morbid obesity. Obes Surg. 2011;21:139-45.
13. Di Betta E, Mittempergher F, Nascimbeni R, et al. Outcome of duodenal switch with a transitory vertical gastroplasty, in super-super-obese patients in an 8-year series. Obes Surg. 2008;18:182-6.
14. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 1997;20:1183-97.
15. Waist circumference and waist-hip-ratio. Report of a WHO Expert Consultation, Geneva 8-11 December 2008. Ed. World Health Organization; 2011.
16. Lean ME, Han TS, Morrison CE. Waist circumference as a measure for indicating need for weight management. BMJ. 1995;15(311(6998)):158-61.
17. Cordido F, Alvarez-Castro P, Isidro ML, et al. Comparison between insulin tolerance test, growth hormone (GH)-releasing hormone (GHRH), GHRH plus acipimox and GHRH plus GH-releasing peptide-6 for the diagnosis of adult GH deficiency in normal subjects, obese and hypopituitary patients. Eur J Endocrinol. 2003;149:117-22.
18. Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormones secretion in experimental animals and the human. Endocr Rev. 1998;19:717-97.
19. Maccario M, Tassone F, Grottoli S, et al. Neuroendocrine and metabolic determinants of the adaptation of GH/IGF-1 axis to obesity. Ann Endocrinol. 2002;63:140-4.
20. Savastano S, Di Somma C, Mentone A, et al. Growth hormone insufficiency in obese patients. J Endocrinol Invest. 2006;29:536-44.
21. Sabin MA, De Hora M, Holly JM, et al. Fasting non-esterified fatty acid profiles in childhood and their relationship with adiposity, insulin sensitivity and lipid levels. Pediatrics. 2007;120:1426-33.
22. Baxter RC. The binding protein's binding protein: clinical applications of acid-labile subunit (ALS) measurement. J Clin Endocrinol Metab. 1997;82:956-61.
23. Marzullo P, Di Somma C, Prat KL, et al. Usefulness of different biochemical markers of the insulin-like growth factor (IGF) family in diagnosing growth hormone excess and deficiency in adults. J Clin Endocrinol Metab. 2001;86:3001-8.
24. Gòmez JM, Maravall FJ, Gòmez N, et al. The IGF-1 system component concentrations that decrease with ageing are lower in obesity in relationship to body mass index and body fat. Growth Horm IGF Res. 2004;14:91-6.
25. Maccario M, Grottoli S, Procopio M, et al. The GH/IGF-1 axis in obesity: influence of neuro-endocrine and metabolic factors. Int J Obes Relat Metab Disord. 2000;24 Suppl 2:S96-9.
26. Di Somma C, Angrisani L, Rota F, et al. GH and IGF-1 deficiency are associated with reduced loss of fat mass after laparoscopic-adjustable silicone gastric banding. Clin Endocrinol. 2008;69:393-9.
27. Savastano S, Angrisani L, Di Somma C, et al. Relationship between growth hormone/insulin like growth factor-1 axis and voluntary weight loss after gastric banding surgery for severe obesity. Obes Surg. 2010;20:211-20.
28. De Marinis L, Bianchi A, Mancini A, et al. Growth hormone secretion and leptin in morbid obesity before and after biliopancreatic diversion: relationships with insulin and body composition. J Clin Endocrinol Metab. 2004;89:174-80.
29. Misra M, Bredella MA, Tsai P, et al. Lower growth hormone and higher cortisol are associated with greater visceral adiposity, intramyocellular lipids, and insulin resistance in overweight girls. Am J Physiol Endocrinol Metab. 2008;295:E385-92.
30. Franco C, Bengtsson BA, Johannsson G. Visceral obesity and the role of the somatotropic axis in the development of metabolic complications. Growth Horm IGF Res. 2001;11:5097-102.
31. Harvey RA, Champe PC, editors. Lippincott's illustrated review - pharmacology. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2008.